These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors. Wilcox CM; Seay T; Arcury J; Hirschowitz BI Scand J Gastroenterol; 2011 Mar; 46(3):277-80. PubMed ID: 21073392 [TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with Zollinger-Ellison syndrome. Mignon M; Pospai D; Forestier S; Vatier J; Vallot T Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592 [TBL] [Abstract][Full Text] [Related]
4. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Hirschowitz BI; Simmons J; Mohnen J Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694 [TBL] [Abstract][Full Text] [Related]
5. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome]. Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984 [TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Hirschowitz BI; Mohnen J; Shaw S Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753 [TBL] [Abstract][Full Text] [Related]
7. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. Hirschowitz BI; Worthington J; Mohnen J; Haber M Aliment Pharmacol Ther; 2007 Sep; 26(6):869-78. PubMed ID: 17767471 [TBL] [Abstract][Full Text] [Related]
8. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Morocutti A; Merrouche M; Bjaaland T; Humphries T; Mignon M Aliment Pharmacol Ther; 2006 Nov; 24(10):1439-44. PubMed ID: 17081164 [TBL] [Abstract][Full Text] [Related]
9. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045 [TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Hirschowitz BI; Mohnen J; Shaw S Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754 [TBL] [Abstract][Full Text] [Related]
11. Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy. Mayer A; Sheiner E; Holcberg G Arch Gynecol Obstet; 2007 Aug; 276(2):171-3. PubMed ID: 17318560 [TBL] [Abstract][Full Text] [Related]
12. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Jensen RT; Metz DC; Koviack PD; Feigenbaum KM Aliment Pharmacol Ther; 1993; 7 Suppl 1():41-50, discussion 61-6. PubMed ID: 8490079 [TBL] [Abstract][Full Text] [Related]
13. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. McArthur KE; Richardson CT; Barnett CC; Eshaghi N; Smerud MJ; McClelland RN; Feldman M Am J Gastroenterol; 1996 Jun; 91(6):1104-11. PubMed ID: 8651153 [TBL] [Abstract][Full Text] [Related]
14. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Metz DC; Pisegna JR; Ringham GL; Feigenbaum K; Koviack PD; Maton PN; Gardner JD; Jensen RT Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437 [TBL] [Abstract][Full Text] [Related]
15. Costs and risks in the management of patients with gastric acid hypersecretion. Hirschowitz BI; Fineberg N; Wilcox CM; Mohnen J; Worthington J J Clin Gastroenterol; 2010 Jan; 44(1):28-33. PubMed ID: 19581810 [TBL] [Abstract][Full Text] [Related]
16. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Raufman JP; Collins SM; Pandol SJ; Korman LY; Collen MJ; Cornelius MJ; Feld MK; McCarthy DM; Gardner JD; Jensen RT Gastroenterology; 1983 Jan; 84(1):108-13. PubMed ID: 6128284 [TBL] [Abstract][Full Text] [Related]
17. Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. Wilcox CM; Martin T; Phadnis M; Mohnen J; Worthington J; Hirschowitz BI BMC Gastroenterol; 2008 May; 8():18. PubMed ID: 18507843 [TBL] [Abstract][Full Text] [Related]
18. Case presentation of gastrinoma combined with gastric carcinoid with the longest survival record -- Zollinger-Ellison syndrome: pathophysiology, diagnosis and therapy. Konturek SJ; Konturek PC; Bielański W; Lorens K; Sito E; Konturek JW; Kwiecień S; Bobrzyński A; Pawlik T; Karcz D; Areny H; Stachura T Med Sci Monit; 2002 Jun; 8(6):CS43-59. PubMed ID: 12070442 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Hirschowitz BI; Simmons J; Mohnen J Clin Gastroenterol Hepatol; 2005 Jan; 3(1):39-48. PubMed ID: 15645403 [TBL] [Abstract][Full Text] [Related]
20. Long-term follow up of patients with Zollinger-Ellison syndrome (ZES). Lind T; Olbe L Acta Chir Scand; 1989 Aug; 155(8):383-8. PubMed ID: 2574521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]